Morishita, N. et al. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector. Biochem. Biophys. Res. Commun. 334, 1121-1126

Department of Gastroenterological Surgery, Transplant, and Surgical Oncology, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan.
Biochemical and Biophysical Research Communications (Impact Factor: 2.3). 10/2005; 334(4):1121-6. DOI: 10.1016/j.bbrc.2005.06.204
Source: PubMed


To enter the realm of human gene therapy, a novel drug delivery system is required for efficient delivery of small molecules with high safety for clinical usage. We have developed a unique vector "HVJ-E (hemagglutinating virus of Japan-envelope)" that can rapidly transfer plasmid DNA, oligonucleotide, and protein into cells by cell-fusion. In this study, we associated HVJ-E with magnetic nanoparticles, which can potentially enhance its transfection efficiency in the presence of a magnetic force. Magnetic nanoparticles, such as maghemite, with an average size of 29 nm, can be regulated by a magnetic force and basically consist of oxidized Fe which is commonly used as a supplement for the treatment of anemia. A mixture of magnetite particles with protamine sulfate, which gives a cationic surface charge on the maghemite particles, significantly enhanced the transfection efficiency in an in vitro cell culture system based on HVJ-E technology, resulting in a reduction in the required titer of HVJ. Addition of magnetic nanoparticles would enhance the association of HVJ-E with the cell membrane with a magnetic force. However, maghemite particles surface-coated with heparin, but not protamine sulfate, enhanced the transfection efficiency in the analysis of direct injection into the mouse liver in an in vivo model. The size and surface chemistry of magnetic particles could be tailored accordingly to meet specific demands of physical and biological characteristics. Overall, magnetic nanoparticles with different surface modifications can enhance HVJ-E-based gene transfer by modification of the size or charge, which could potentially help to overcome fundamental limitations to gene therapy in vivo.

Download full-text


Available from: Ryuichi Morishita,
  • Source
    • "Th e use of MNPs to increase the eff ectiveness of the cellfusion vector hemagglutinating virus Japan envelope (HVJ-E) was represented by Morishita and others. Th ey found that by associating protamine sulfate (PS)-coated MNPs to HVJ-E, transfection was improved in vitro in BHK21 cells, even with a reduction in the amount of HVJ-E and no proof of toxicity (Dobson 2006, Morishita et al. 2005 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gene therapy is defined as the direct transfer of genetic material to tissues or cells for the treatment of inherited disorders and acquired diseases. For gene delivery, magnetic nanoparticles (MNPs) are typically combined with a delivery platform to encapsulate the gene, and promote cell uptake. Delivery technologies that have been used with MNPs contain polymeric, viral, as well as non-viral platforms. In this review, we focus on targeted gene delivery using MNPs.
    Artificial Cells 03/2015; DOI:10.3109/21691401.2015.1014093 · 1.02 Impact Factor
  • Source
    • "MNPs coated with heparin increase the transfection efficiency in vivo. Therefore, the surface chemistry of the MNPs needs to be tailored to meet special demands (Morishita et al. 2005, Yi et al. 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Magnetic iron oxide nanoparticles have become the main candidates for biomedical and biological applications, and the application of small iron oxide nanoparticles in in vitro diagnostics has been practiced for about half a century. Magnetic nanoparticles (MNPs), in combination with an external magnetic field and/or magnetizable grafts, allow the delivery of particles to the chosen target area, fix them at the local site while the medication is released, and act locally. In this review, we focus mostly on the potential use of MNPs for biomedical and biotechnological applications, and the improvements made in using these nanoparticles (NPs) in biological applications.
    Artificial Cells 01/2015; DOI:10.3109/21691401.2014.998832 · 1.02 Impact Factor
  • Source
    • "Therefore, there has been an ongoing effort to study and develop non-viral vectors with an efficiency comparable to that of viral-based vectors. Delivery complexes based on cationic lipids, cationic polyplexes, peptides, and metal nanoparticles have been reported (Amand et al. 2012; Zhang et al. 2008; Ryou et al. 2011; Tang and Hughes 1998; Morishita et al. 2005; Mintzer and Simanek 2009; Lemkine and Demeneix 2001; Parker et al. 2003). Our research is focused on exploiting the cellular transport machinery based on the dynein motor complex to enhance plasmid DNA (pDNA) trafficking via the cytosol, thereby increasing the transfection efficiency. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dynein light chains mediate the interaction between the cargo and the dynein motor complex during retrograde microtubule-mediated transport in eukaryotic cells. In this study, we expressed and characterized the recombinant human dynein light chain Rp3 and developed a modified variant harboring an N-terminal DNA-binding domain (Rp3-Db). Our approach aimed to explore the retrograde cell machinery based on dynein to enhance plasmid DNA (pDNA) traffic along the cytosol toward the nucleus. In the context of non-viral gene delivery, Rp3-Db is expected to simultaneously interact with DNA and dynein, thereby enabling a more rapid and efficient transport of the genetic material across the cytoplasm. We successfully purified recombinant Rp3 and obtained a low-resolution structural model using small-angle X-ray scattering. Additionally, we observed that Rp3 is a homodimer under reducing conditions and remains stable over a broad pH range. The ability of Rp3 to interact with the dynein intermediate chain in vitro was also observed, indicating that the recombinant Rp3 is correctly folded and functional. Finally, Rp3-Db was successfully expressed and purified and exhibited the ability to interact with pDNA and mediate the transfection of cultured HeLa cells. Rp3-Db was also capable of interacting in vitro with dynein intermediate chains, indicating that the addition of the N-terminal DNA-binding domain does not compromise its function. The transfection level observed for Rp3-Db is far superior than that reported for protamine and is comparable to that of the cationic lipid Lipofectamine(TM). This report presents an initial characterization of a non-viral delivery vector based on the dynein light chain Rp3 and demonstrates the potential use of modified human light chains as gene delivery vectors.
    Applied Microbiology and Biotechnology 09/2013; 98(8). DOI:10.1007/s00253-013-5239-5 · 3.34 Impact Factor
Show more